BioCentury
ARTICLE | Distillery Therapeutics

Cancer

September 13, 2017 5:07 PM UTC

Cell culture and mouse studies suggest inhibiting ROCK2 could help treat MYCN-amplified neuroblastomas. In MYCN-amplified human neuroblastoma cell lines, a ROCK2 inhibitor decreased differentiation, migration and invasiveness compared with vehicle. In a xenograft mouse model of MYCN-amplified neuroblastoma and a transgenic mouse model of neuroblastoma caused by MYCN overexpression, the ROCK2 inhibitor decreased tumor growth compared with vehicle. Next steps could include testing ROCK2 inhibitors in additional neuroblastoma models...